Related Experiment Video
Updated: Jan 2, 2026
12:43
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
12.2K
Palm Tocotrienol-Adjuvanted Dendritic Cells Decrease Expression of the SATB1 Gene in Murine Breast Cancer Cells and
Sitti Rahma Abdul Hafid1,2, Ammu Kutty Radhakrishnan2,3
1.Malaysian Palm Oil Board, 6 Persiaran Institusi, Bandar Baru Bangi, Selangor 43000, Malaysia.
Vaccines
|December 1, 2019
Summary
Tocotrienol-rich fraction (TRF) supplementation potentiates dendritic cell (DC) vaccine immunotherapy for breast cancer. Combining TRF with DC vaccines significantly reduced tumor size and improved survival rates in mice by enhancing anti-tumor immune responses.
Area of Science:
- Immunology
- Oncology
- Nutritional Science
Background:
- Dendritic cell (DC) vaccines are a promising immunotherapy for cancer.
- Tocotrienol-rich fraction (TRF) is a natural compound with potential anti-cancer properties.
- Combining DC vaccines with TRF may enhance anti-tumor immune responses.
Purpose of the Study:
- To evaluate the effectiveness of DC-vaccine immunotherapy combined with TRF supplementation in potentiating anti-tumor immune responses.
- To investigate the effects of this combination therapy on tumor growth, survival rates, and immune cell activation markers.
- To analyze gene and protein expression changes in tumors treated with DC-vaccine and TRF.
Main Methods:
- Breast cancer was induced in BALB/c mice.
- Mice received DC-vaccine immunotherapy with or without daily TRF supplementation.
- Peripheral blood and tumor tissues were collected for analysis.
- Flow cytometry was used to analyze immune cell surface molecules (CD40, CD80, CD83, CD86).
- Microarray and Western blotting were performed to analyze gene and protein expression.
Main Results:
- Combination therapy (DC + TL + TRF) significantly reduced tumor size and increased survival rates (p < 0.05).
- Upregulation of immune cell activation markers (CD40, CD80, CD83, CD86) and FasL was observed in the combination group.
- Lower expression of the SATB1 gene, associated with aggressive breast cancer growth, was found in tumors from the combination group.
Conclusions:
- TRF supplementation potentiates the effectiveness of DC-vaccine immunotherapy.
- The combination therapy enhances anti-tumor immune responses and reduces tumor growth.
- Further research is warranted to explore the molecular mechanisms of SATB1 in breast cancer and its interaction with DC vaccines and TRF.
